| goserelin acetate / Generic mfg. |
NCT00010010: Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | | US | exemestane, goserelin acetate | NYU Langone Health, National Cancer Institute (NCI) | Breast Cancer | 05/01 | | | |
NCT00235937: Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex |
|
|
| Completed | 2 | 45 | Europe | Anastrozole and goserelin | AstraZeneca | Breast Cancer | | 12/06 | | |
NCT00217659: S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 0 | US | anastrozole, goserelin acetate | Southwest Oncology Group, National Cancer Institute (NCI) | Breast Cancer | 01/07 | 01/07 | | |
NCT00303524: Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients |
|
|
| Completed | 2 | 170 | Japan | Goserelin acetate, Zoladex | AstraZeneca | Breast Cancer | 08/07 | 02/09 | | |
NCT00498901: Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer |
|
|
| Terminated | 2 | 1 | US | goserelin, letrozole, leuprolide acetate, conventional surgery | University of Washington, National Cancer Institute (NCI) | Breast Cancer | 12/07 | 11/08 | | |
NCT00532272: Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC |
|
|
| Completed | 2 | 78 | RoW | Letrozole ,Goserelin, Femara, Zoladex | National Cancer Center, Korea | Metastatic Breast Cancer | 04/08 | 08/10 | | |
| Completed | 2 | 62 | Europe | Goserelin | German Breast Group | Breast Cancer | 12/08 | 03/10 | | |
NCT00322348 / 2005-004001-29: Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women |
|
|
| Completed | 2 | 98 | Europe, RoW | Goserelin acetate, Zoladex® | AstraZeneca | Advanced Breast Cancer | | 11/09 | | |
NCT01013506: Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 0 | US | IGF-1R inhibitor OSI-906, erlotinib hydrochloride, Tarceva, goserelin, Zoladex, letrozole, Femara | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Breast Cancer | 12/09 | 12/09 | | |
NCT01205685: Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer |
|
|
| Terminated | 2 | 11 | US | OSI-906, Erlotinib, Letrozole, Goserelin | Vanderbilt-Ingram Cancer Center | Hormone-sensitive Metastatic Breast Cancer | 07/11 | 07/11 | | |
NCT01240941: Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer |
|
|
| Withdrawn | 2 | 0 | US | MK-2206, Exemestane, Goserelin | Vanderbilt-Ingram Cancer Center | Metastatic Breast Cancer | 06/12 | 12/12 | | |
NCT01368263: Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer |
|
|
| Terminated | 2 | 8 | US | goserelin acetate, ICI-118630, ZDX, Zoladex, letrozole, CGS 20267, Femara, LTZ, anastrozole, ANAS, Arimidex, ICI-D1033, chemotherapy, chemo, Surgery | Washington University School of Medicine, National Cancer Institute (NCI) | Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer | 05/13 | 05/13 | | |
NCT01776008: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer |
|
|
| Terminated | 2 | 16 | US | Akt Inhibitor MK2206, MK2206, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Neoadjuvant Therapy, Induction Therapy, Neoadjuvant, Preoperative Therapy, Pharmacological Study, Therapeutic Conventional Surgery | National Cancer Institute (NCI) | Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer | 05/15 | 05/15 | | |
